As the IPF treatment landscape evolves, developers must consider how to design therapies that stand out not only scientifically but also clinically and commercially. This interactive discussion will explore how to ensure new treatments demonstrate enough value for clinical adoption, regulatory approval, and long-term reimbursement success.

• Setting a Higher Bar for Efficacy: Assessing whether small reductions in lung function decline are enough, or if novel therapies need to show broader benefits in patient well-being and disease modification
• Trial Design for Differentiation: Exploring how study endpoints, patient selection, and biomarker strategies can help new therapies stand out in a space where standard-ofcare options are expanding
• The Reality of Combination Therapy: Discussing how to evaluate the standalone and additive effects of therapies that will likely be used in combination rather than as monotherapies
• Future Considerations for Reimbursement: Examining how payers might assess value when multiple treatment options exist, and whether cost-effectiveness modeling should be incorporated into early development strategies.